Birch Allergy Treatment Market

Birch Allergy Treatment Market Size, Market Forecast and Outlook By FMI

The birch allergy treatment market was valued at USD 653.7 million in 2025. The market is set to reach USD 699.5 million by 2026-end and grow at a CAGR of 7.0% between 2026-2036 to reach USD 1,376.0 million by 2036. Antihistamines will dominate with a 48.9% share, while Oral will lead with a 56.7% share.

Summary of the Birch Allergy Treatment Market

• Demand and Growth Drivers
  • High prevalence of birch pollen sensitization across temperate climate populations in Europe, North America, and East Asia sustains baseline demand for symptomatic relief medications during annual pollen seasons.
  • Growing adoption of sublingual allergen immunotherapy as a disease modifying treatment approach is creating premium pharmaceutical revenue streams beyond traditional antihistamine based symptom management.
  • Climate change related extension of pollen seasons and geographic expansion of birch pollen distribution are increasing the duration and geographic scope of birch allergy symptom burden, expanding treatment demand.
• Product and Segment View
  • Antihistamines hold 48.9% of the Drug Class segment in 2026, reflecting their established position as the most widely used first line symptomatic treatment for birch pollen allergic rhinitis and conjunctivitis.
  • Seasonal Allergic Rhinitis accounts for 68.5% of the Allergy Type segment, reflecting the predominant clinical presentation of birch pollen allergy as seasonal nasal and ocular symptoms during spring pollen seasons.
  • Retail Pharmacy at 51.8% of the Distribution Channel segment reflects the primary treatment setting and dispensing pathway for birch allergy medications.
• Geography and Competitive Outlook
  • China leads growth at 8.2% CAGR through 2036, reflecting increasing allergic rhinitis prevalence driven by urbanization and air quality changes, growing allergy specialist capacity, and expanding awareness of immunotherapy treatment options.
  • The USA at 7.8% reflects high allergic rhinitis prevalence, established allergy specialist referral networks, and growing adoption of sublingual immunotherapy as a convenient alternative to injection based desensitization.
  • Companies that combine antihistamine portfolios with allergen immunotherapy products and diagnostic testing partnerships are positioned to capture the full spectrum of birch allergy treatment from symptom relief through disease modification.
• Analyst Opinion
  • Sabyasachi Ghosh, Principal Consultant at FMI says, 'The birch allergy treatment market is transitioning from symptom management toward disease modification through sublingual and subcutaneous allergen immunotherapy. Companies that combine symptom relief antihistamine portfolios with disease modifying immunotherapy products and diagnostic testing partnerships will capture the full spectrum of birch allergy treatment revenue from first presentation through long term management.'
  • The birch allergy treatment market is transitioning toward more structured procurement and supply chain relationships.
  • Adoption is increasing due to evolving regulatory requirements and commercial benchmarks.
  • Demand is further supported by evolving standards across North America, Europe, and East Asia.

Key Takeaways, Market Size, and Forecast

• The birch allergy treatment market was valued at USD 653.77 million in 2025.
• By 2036, the Birch Allergy Treatment Market is expected to be worth USD 1,376.03 million.
• From 2026 to 2036, the market is projected to expand at a CAGR of 7%.
• The market is projected to create an incremental opportunity of USD 676.52 million between 2026 and 2036.
• In 2026, Antihistamines is expected to account for 48.9% of the Drug Class, driven by high prevalence of birch pollen sensitization in temperate climate populations, established efficacy of oral antihistamines for symptom control, and wide over the counter availability across pharmacy and retail channels.
• China (8.2%) and USA (7.8%) are two of the fastest growing markets in the world.

Birch Allergy Treatment Market Definition

The birch allergy treatment market encompasses pharmaceutical products used to treat allergic reactions to birch pollen (Betula species), including symptomatic relief medications and disease modifying allergen immunotherapy. Treatment categories include antihistamines, intranasal corticosteroids, leukotriene receptor antagonists, subcutaneous allergen immunotherapy, and sublingual allergen immunotherapy tablets.

Birch Allergy Treatment Market Inclusions

Market scope covers all commercially marketed birch allergy treatment products categorized by Drug Class, Route of Administration, Distribution Channel, Treatment Type, Allergy Type, End User. Revenue sizing spans the 2026 to 2036 forecast period.

Birch Allergy Treatment Market Exclusions

The scope does not include general allergy diagnostic testing services, air purification devices, pollen barrier products, or allergen immunotherapy products targeting non birch pollen allergens.

Birch Allergy Treatment Market Research Methodology

• Primary Research: FMI analysts conducted interviews with manufacturers, specialists, and participants across key markets.
• Desk Research: Combined industry databases, regulatory filings, publications, and manufacturer disclosures.
• Market Sizing and Forecasting: Bottom up aggregation across segments, applications and regions with adoption curve modeling
• Data Validation: Verified quarterly against statistics, trade data and reported figures.

Why is the Birch Allergy Treatment Market Growing?

• The birch pollen season recurs each year, ensuring predictable, cyclical demand for symptomatic treatment medications, with antihistamines, intranasal corticosteroids and eye drops generating consistent pharmacy sales during spring months.
• Sublingual tablet formats are growing in popularity for allergen immunotherapy, offering convenient, at-home treatment options for traditional subcutaneous injection protocols that require clinic visits.
• China drives growth at 8.2% CAGR on the back of rising prevalence of allergic rhinitis, growing allergy specialist infrastructure, and increasing consumer awareness of the available treatment options.

The market for birch allergy treatment is growing with increasing prevalence of allergic rhinitis and shift of treatment from symptomatic relief to disease modification. The drug class segment is dominated by antihistamines, with a 48.9% share, reflecting their position as the most easily accessible and widely used treatment for symptoms of birch pollen allergy. Second generation non-sedating antihistamines are the most widely prescribed. Cetirizine, loratadine and fexofenadine are available as both prescription and over the counter formulations.

Allergen immunotherapy is the fastest growing treatment class in the birch allergy market. Sublingual immunotherapy tablets for birch pollen allergens provide a convenient, home administered treatment protocol that induces immune tolerance and results in disease modification over three to five-year treatment courses. ALK-Abello and Stallergenes Greer have developed birch pollen specific sublingual products that generate premium per patient revenue versus symptomatic antihistamine treatment.

Climate change is opening up the birch allergy treatment market by lengthening the pollen season and expanding its geographic reach. The birch pollen season has been linked to earlier start and later end with warmer temperatures, resulting in more days with symptoms per year. Birch species range is moving north, exposing populations in these regions to birch pollen where previously it was minimal. This creates new patient populations for both symptomatic treatment and immunotherapy.

Market Segmentation Analysis

• Antihistamines holds 48.9% of the Drug Class segment.
• Seasonal Allergic Rhinitis accounts for 68.5% of the Allergy Type segment.
• Retail Pharmacy at 51.8% of the Distribution Channel segment reflects functional preferences.

The birch allergy treatment market is segmented by Drug Class, Route of Administration, Distribution Channel, Treatment Type, Allergy Type, End User.

Insights into the Antihistamines Drug Class Segment

In 2026, Antihistamines is expected to account for 48.9% of the Drug Class segment. This reflects sustained demand where antihistamines has demonstrated consistent performance. Sub segments are differentiated by specifications and pricing. Procurement decisions prioritize reliability, compliance, and quality.

Insights into the Seasonal Allergic Rhinitis Allergy Type Segment

Seasonal Allergic Rhinitis is the dominating segment of Allergy Type with 68.5%. Market expansion and standardization drive growth. Buyers want performance, cost and support.

Birch Allergy Treatment Market Drivers, Restraints, and Opportunities

• Regulatory frameworks create demand for compliant products in a structured way.
• Margin risks stem from cost constraints and supply limitations.
• Application expansion drives incremental growth opportunities.

The birch allergy treatment market is shaped by regulatory mandates, shifting requirements, and competitive dynamics.

Seasonal Prevalence and Recurring Treatment Demand

Demand is shaped by the annual recurrence of birch pollen seasons that generate predictable, cyclical treatment demand. Birch pollen is the dominant tree pollen allergen in temperate climate zones, with sensitization rates ranging from 15 to 30% of the population in heavily affected regions of Northern and Central Europe, Scandinavia, and parts of North America and East Asia.

Over the Counter Availability and Prescription Switching

Growth is constrained in the antihistamine segment by the shift of second generation antihistamines from prescription to over the counter status, which reduces per unit pricing and physician involvement in treatment selection. OTC availability improves patient access but limits manufacturer ability to capture premium pricing and reduces the clinical touchpoints that could lead to immunotherapy referral.

Allergen Immunotherapy Adoption and Disease Modification

Adoption is increasing due to growing acceptance of sublingual allergen immunotherapy as a convenient, disease modifying treatment option. Sublingual tablets that can be administered at home eliminate the clinic visit requirement of traditional subcutaneous injection immunotherapy, reducing treatment burden and improving compliance. Three to five year treatment courses generate sustained pharmaceutical revenue per patient.

Climate Change and Pollen Season Extension

Growth reflects the documented impact of climate change on birch pollen production and distribution. Earlier season onset, longer season duration, and geographic range expansion are increasing the cumulative pollen exposure burden on sensitized populations. This environmental trend structurally expands the birch allergy treatment market by increasing both the number of affected individuals and the duration of annual treatment need.

Analysis of Birch Allergy Treatment Market By Key Countries

Country	CAGR
USA	7.8%
UK	7.2%
France	7.3%
Germany	7.5%
Italy	6.8%
South Korea	6.5%
Japan	6.3%
China	8.2%
Australia - New Zealand	6.9%

• China leads with 8.2% CAGR through 2036.
• USA at 7.8% demonstrates sustained demand.
• UK (7.2%) reflects steady demand.

The global birch allergy treatment market is projected to grow at 7% CAGR from 2026 to 2036, covering more than 30 countries.

Demand Outlook for Birch Allergy Treatment Market in the United States

The United States is expected to grow at 7.8% CAGR through 2036. Birch pollen sensitization rates of 15 to 25% in northern states sustain seasonal symptomatic treatment demand, with growing allergist adoption of sublingual immunotherapy tablets as convenient alternatives to traditional allergy injection protocols creating premium pharmaceutical revenue beyond antihistamine sales.

• Northern state birch pollen sensitization sustains seasonal treatment demand.
• Allergist adoption of sublingual immunotherapy creates premium revenue streams.
• Over the counter antihistamine availability sustains accessible symptomatic relief.

Future Outlook for Birch Allergy Treatment Market in the United Kingdom

The United Kingdom is expected to grow at 7.2% CAGR through 2036. The UK birch pollen season affects a substantial proportion of hay fever sufferers in England and Wales, with NHS allergy services increasingly offering sublingual immunotherapy for patients with severe birch pollen allergy that significantly impairs quality of life despite optimal pharmacotherapy.

• Birch pollen is a major contributor to UK hay fever burden.
• NHS allergy services increasingly offer sublingual immunotherapy for severe cases.
• Community pharmacy OTC antihistamine sales sustain accessible symptomatic treatment.

Opportunity Analysis of Birch Allergy Treatment Market in Germany

Germany is expected to grow at 7.5% CAGR through 2036. Germany has the highest birch pollen sensitization rates in Central Europe, with established allergology specialist networks, statutory health insurance reimbursement for allergen immunotherapy, and companies like ALK-Abello and Stallergenes Greer maintaining strong market positions in sublingual and subcutaneous birch pollen treatment products.

• Highest Central European birch sensitization rates sustain treatment demand.
• Statutory health insurance reimburses allergen immunotherapy.
• Established allergology specialist networks support treatment initiation and monitoring.

In-depth Analysis of Birch Allergy Treatment Market in China

China is expected to grow at 8.2% CAGR through 2036. Rising allergic rhinitis prevalence in Chinese urban populations, driven by air quality changes and the hygiene hypothesis, is expanding the birch pollen sensitized population, with growing allergy specialist capacity and increasing awareness of immunotherapy options creating conditions for market development beyond traditional antihistamine use.

• Rising allergic rhinitis prevalence expands the sensitized population.
• Growing allergy specialist capacity supports immunotherapy adoption.
• Urbanization and air quality changes increase allergic sensitization rates.

Sales Analysis of Birch Allergy Treatment Market in France

France is expected to grow at 7.3% CAGR through 2036. French birch pollen sensitization is concentrated in northern and eastern regions, with Stallergenes Greer's French headquarters supporting strong domestic market presence for allergen immunotherapy products and the French healthcare system providing reimbursement for both subcutaneous and sublingual desensitization protocols.

• Northern and eastern regional birch pollen exposure drives localized treatment demand.
• Stallergenes Greer domestic presence supports strong immunotherapy market position.
• Healthcare system reimbursement covers both SCIT and SLIT treatment protocols.

In-depth Analysis of Birch Allergy Treatment Market in Japan

Japan is expected to grow at 6.3% CAGR through 2036. While cedar pollen (sugi) dominates the Japanese pollen allergy landscape, birch pollen sensitization is significant in Hokkaido and northern Honshu, with Japanese allergists managing birch allergy using both imported immunotherapy products and domestically developed desensitization protocols.

• Birch pollen sensitization is regionally concentrated in Hokkaido and northern Honshu.
• Cedar pollen dominance creates a market context where birch is a secondary allergen.
• Domestically developed desensitization protocols complement imported immunotherapy products.

Competitive Landscape and Strategic Positioning

• ALK-Abelló A/S maintains the strongest position through capability and portfolio breadth.
• Stallergenes Greer plc, Allergy Therapeutics Plc, HAL Allergy Group compete through specialization and expertise.
• Emerging players focus on niche applications and differentiation.

ALK-Abelló A/S holds the strongest competitive position through technical capability, established relationships, and portfolio breadth.

Stallergenes Greer plc, Allergy Therapeutics Plc, HAL Allergy Group compete through specialized capabilities, application expertise, and targeted market strategies.

Barriers to entry include technical expertise, regulatory compliance, established relationships, and capital requirements.

Strategic priorities include cost optimization, geographic expansion, portfolio extension, and customer retention investment.

Key Companies in the Birch Allergy Treatment Market

Key global companies leading the birch allergy treatment market include:

• ALK-Abelló A/S, Stallergenes Greer plc, Allergy Therapeutics Plc, HAL Allergy Group maintain strong positions through integrated capabilities.
• Regeneron Pharmaceuticals Inc, Desentum, Roxall Medizin GmbH compete through regional specialization.
• Worg Pharmaceuticals AG, S-TARget therapeutics GmbH, Adamis Pharmaceuticals Corporation, Merck KGaA, ASIT biotech, Anergis S.A., Novartis AG, Circassia Pharmaceuticals, Johnson & Johnson Services, Inc., Biomay AG, Mylan N.V., Hollister Stier Laboratories, Generex Biotechnology Corporation are establishing presence through niche focus.

Competitive Benchmarking: Birch Allergy Treatment Market

Company	Product Portfolio	Immunotherapy Capability	Distribution Reach	Clinical Evidence
ALK-Abelló A/S	High	High	Strong	Global
Stallergenes Greer plc	High	High	Strong	Global
Allergy Therapeutics Plc	High	High	Strong	Global
HAL Allergy Group	Medium	High	Moderate	Global
Regeneron Pharmaceuticals Inc	Medium	Medium	Moderate	Regional
Desentum	Medium	Medium	Moderate	Regional
Roxall Medizin GmbH	Low	Medium	Low	Regional
Worg Pharmaceuticals AG	Low	Medium	Low	Niche
S-TARget therapeutics GmbH	Low	Medium	Low	Niche
Adamis Pharmaceuticals Corporation	Low	Medium	Low	Niche

Source: Future Market Insights competitive analysis, 2026.

Key Developments in Birch Allergy Treatment Market

• In 2025, ALK-Abelló A/S expanded its seasonal allergic rhinitis treatment portfolio after receiving approvals in Europe and Canada for pediatric use of its ITULAZAX®/ITULATEK® tree pollen allergy tablets targeting birch-related allergies.
• In 2025, Stallergenes Greer plc strengthened its China market presence through a long-term partnership with Nuance Pharma for development and commercialization of Actair® allergy immunotherapy products in China.

Key Players in the Birch Allergy Treatment Market

Major Global Players

• ALK-Abelló A/S
• Stallergenes Greer plc
• Allergy Therapeutics Plc
• HAL Allergy Group
• Regeneron Pharmaceuticals Inc
• Desentum
• Roxall Medizin GmbH

Emerging Players/Startups

• Worg Pharmaceuticals AG
• S-TARget therapeutics GmbH
• Adamis Pharmaceuticals Corporation
• Merck KGaA
• ASIT biotech
• Anergis S.A.
• Novartis AG
• Circassia Pharmaceuticals
• Johnson & Johnson Services, Inc.
• Biomay AG
• Mylan N.V.
• Hollister Stier Laboratories
• Generex Biotechnology Corporation

Report Scope and Coverage

Parameter	Details
Quantitative Units	USD 699.50 million to USD 1,376.03 million, at a CAGR of 7%
Market Definition	The birch allergy treatment market encompasses commercially traded products categorized by Drug Class, Route of Administration, Distribution Channel, Treatment Type, Allergy Type, End User.
Regions Covered	North America, Latin America, Europe, East Asia, South Asia and Pacific, Middle East and Africa
Countries Covered	USA, UK, France, Germany, Italy, South Korea, Japan, China, Australia - New Zealand, 30 plus countries
Key Companies Profiled	ALK-Abelló A/S, Stallergenes Greer plc, Allergy Therapeutics Plc, HAL Allergy Group, Regeneron Pharmaceuticals Inc, Desentum, Roxall Medizin GmbH, Worg Pharmaceuticals AG, S-TARget therapeutics GmbH, Adamis Pharmaceuticals Corporation, Merck KGaA, ASIT biotech, Anergis S.A., Novartis AG, Circassia Pharmaceuticals, Johnson & Johnson Services, Inc., Biomay AG, Mylan N.V., Hollister Stier Laboratories, Generex Biotechnology Corporation
Forecast Period	2026 to 2036
Approach	Hybrid bottom up and top down methodology starting with verified transaction data, projecting adoption velocity across segments and regions.

Segmentation

Birch Allergy Treatment Market Segmented by Drug Class:

• Antihistamines
  • Second-Generation Antihistamines
  • First-Generation Antihistamines
• Cetirizine
  • Non-Sedating Antihistamine
  • Once-Daily Allergy Relief
• Diphenhydramine
  • Sedating Antihistamine
  • Night-Time Allergy Relief
• Decongestants
  • Nasal Congestion Relief Agents
  • Combination Allergy Medications
• Pseudoephedrine
  • Oral Decongestant Tablets
  • Sinus Pressure Relief
• Oxymetazoline
  • Topical Nasal Spray
  • Short-Term Congestion Relief

Birch Allergy Treatment Market Segmented by Route of Administration:

• Oral
  • Tablets & Capsules
  • Syrups for Pediatric Use
• Intranasal
  • Nasal Sprays
  • Fast-Acting Allergy Relief

Birch Allergy Treatment Market Segmented by Distribution Channel:

• Retail Pharmacy
  • Over-the-Counter (OTC) Sales
  • Community Pharmacies
• Hospital Pharmacy
  • Allergy Treatment Prescriptions
  • Inpatient Care Supply
• Online Pharmacy
  • E-Pharmacy OTC Products
  • Home Delivery Allergy Medications

Birch Allergy Treatment Market Segmented by Treatment Type:

• Pharmacotherapy
  • Antihistamines & Decongestants
  • Combination Allergy Medications
• Immunotherapy
  • Allergen-Specific Immunotherapy (AIT)
  • Subcutaneous & Sublingual Immunotherapy
• Supportive Care
  • Nasal Irrigation
  • Symptom Relief Therapies

Birch Allergy Treatment Market Segmented by Allergy Type:

• Seasonal Allergic Rhinitis
  • Pollen-Induced Allergy
  • Spring Season Allergies
• Oral Allergy Syndrome (OAS)
  • Cross-Reactivity with Foods
  • Mild Oral Symptoms
• Allergic Conjunctivitis
  • Eye Irritation & Redness
  • Watery Eyes

Birch Allergy Treatment Market Segmented by End User:

• Hospitals
  • Allergy & Immunology Departments
  • ENT Specialty Units
• Specialty Clinics
  • Allergy Clinics
  • ENT Clinics
• Homecare Settings
  • Self-Medication (OTC Use)
  • At-Home Allergy Management

Birch Allergy Treatment Market by Region:

• North America
  • USA
  • Canada
  • Mexico
• Latin America
  • Brazil
  • Chile
  • Rest of Latin America
• Western Europe
  • Germany
  • UK
  • Italy
  • Spain
  • France
  • Nordic
  • BENELUX
  • Rest of Western Europe
• Eastern Europe
  • Russia
  • Poland
  • Hungary
  • Balkan & Baltic
  • Rest of Eastern Europe
• East Asia
  • China
  • Japan
  • South Korea
• South Asia and Pacific
  • India
  • ASEAN
  • Australia & New Zealand
  • Rest of South Asia and Pacific
• Middle East & Africa
  • Kingdom of Saudi Arabia
  • Other GCC Countries
  • Turkiye
  • South Africa
  • Other African Union
  • Rest of Middle East & Africa

Research Sources and Bibliography

• 1. European Academy of Allergy and Clinical Immunology. (2025). EAACI Guidelines: Allergic Rhinitis Treatment and Immunotherapy. EAACI.
• 2. World Allergy Organization. (2025). WAO White Book on Allergy: Global Allergic Rhinitis Prevalence. WAO.
• 3. European Medicines Agency. (2024). EMA Assessment Reports: Sublingual Allergen Immunotherapy Products. EMA.
• 4. USA Food and Drug Administration. (2025). FDA Allergenic Products: Pollen Extract Immunotherapy Approvals. FDA.
• 5. World Health Organization. (2025). WHO Climate Change and Health: Aeroallergen Impact Assessment. WHO.

This bibliography is provided for reader reference. The full Future Market Insights report contains the complete reference list with publication dates, URLs, and supporting data for all cited works.

This Report Addresses

• Estimating market size and revenue from 2026 to 2036.
• Segmentation by product, application, end use, and region.
• Insights about more than 30 regional markets.
• Technology, manufacturing, and supply chain analysis.
• Competitive landscape assessment.
• Investment opportunity identification.
• Supply chain and distribution analysis.
• Data delivery in PDF and Excel formats.